Iclusig Deaths Won't Stall FDA's Speedier Drug Approvals

Law360, New York (November 7, 2013, 6:24 PM EST) -- The jarring death toll linked to leukemia drug Iclusig will force the U.S. Food and Drug Administration to revisit the science that won the product accelerated approval, but a growing willingness of seriously ill patients to accept risk means the tragic episode is unlikely to delay other fast-tracked medicines, experts say.

Sales of the chemotherapy drug, which earned FDA clearance in December, were halted last week after manufacturer Ariad Pharmaceuticals Inc. reported that at least 14 fatalities had occurred among 530 patients in two clinical trials....
To view the full article, register now.